AN1 (ASX) Cellmid Zoetis

Originally posted by Taurean7: ↑

There is an obvious lack of understanding of the nature of IP licensing.

A biotech company (here Cellmid) does not engage a partner to carry out research on its behalf on the possible application of its IP towards a diagnostic or therapeutic application.

The partner company pays a contracted initial milestone amount to access the IP for it’s own investigation into a possible application of its own choice. Once it makes that payment it is no longer any of Cellmid’s business how that company chooses to plan and undertake its study. That includes giving any form of a report on progress or on results obtained.

If the partner has reached the point in development that it believes it has a product now ready for commercialisation it normally would need to then contact Cellmid to activate a secondary milestone payment as defined by the contract, allowing it to go forward. That should be the first time that Cellmid formally hears again from the partner. Successful commercialisation normally would involve later royalty payments.

There are many possible reasons for delays, including internal corporate politics and research personnel career changes. There has been some indication that internal politics due to corporate restructuring may apply to the Quest/Celera contract.

There would be no benefit to the partner to have the results of its investigations revealed to anyone prior to being commercialisation ready. If progressing well this might encourage a competitor to commence a similar investigation. If not progressing well for whatever reason, why not let a potential competitor expend the same time and monetary costs to find that out for themselves?

For these reasons it would even be inappropriate for Cellmid to request some indication of progress achieved. Put simply, it is none of Cellmid’s business. There likely would be some form of confidential personal interactions as a matter of courtesy.

Claiming that management is intentionally silent or lax in not reporting on progress simply indicates once again ignorance of the nature of the business. Yet another example of unjustified negativity.

Expand

Originally posted by Taurean7: ↑

Phillit

I have no familiarity with the specific arrangements existing between Cellmid and its licensing partners other than has been released in the relevant ASX announcements or available through passing reference in its various reports. For budding detectives, some clues are available through the ‘licence fees and royalties’ item of financial reports.

I am familiar with the many sources of complexity in IP management and the requirement for confidentiality by both a company and its licensing partner.

Any technical progress or results obtained by a partner become part of its own IP, and there can be no advantage in releasing it, even to the licensing company, unless it has become patent protected. Even indicating whether a program is currently active provides information to a potential competitor.

Cellmid is in a position to provide general updates to shareholders on progress achieved its own product development programs because of the wide patent protection that it holds on the midkine technology.

Expand

Originally posted by tsuba: ↑

I think it needs to be accepted that there are people contributing to this forum who have actual first hand knowledge and experience in the areas that they go to great lengths in explaining to others who have no knowledge in those areas including me.T7 is extremely good at writing concise and easy to understand pros and a credit to him for that too.

Expand

Too late. Already admission no knowledge, just guesswork by the poster you are defending.

No.	Vol.	Price($)
2	197835	0.7¢

No.

Vol.

Price($)

197835

0.7¢

Price($)	Vol.	No.
0.8¢	7500	1

Price($)

Vol.

No.

0.8¢

7500

No.	Vol.	Price($)
2	197835	0.007
4	2016527	0.006
1	300000	0.005
3	600000	0.004
1	600000	0.003

No.

Vol.

Price($)

197835

0.007

2016527

0.006

300000

0.005

600000

0.004

600000

0.003

Price($)	Vol.	No.
0.008	7500	1
0.009	280000	1
0.010	157763	1
0.013	750000	1
0.015	340000	2

Price($)

Vol.

No.

0.008

7500

0.009

280000

0.010

157763

0.013

750000

0.015

340000

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $3.229M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Cellmid Zoetis, page-17

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Is oil undervalued?

GreenX picks up prospective copper project in Germany

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Cellmid Zoetis, page-17

Top Stories

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Is oil undervalued?

GreenX picks up prospective copper project in Germany

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News